BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 23568983)

  • 21. Cerebellar ataxia associated with anti-glutamic acid decarboxylase autoantibodies.
    Vianello M; Tavolato B; Armani M; Giometto B
    Cerebellum; 2003; 2(1):77-9. PubMed ID: 12882238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Usefulness of an anti-mouse cerebellar tissue-derived antigen antibody test in predicting immunotherapy efficacy in patients with idiopathic cerebellar ataxia].
    Ohtomo T; Ogino S; Yanai S; Nakayama S; Yajima R; Sugawara M; Yamada J; Aizawa H; Taguchi T; Nanri K
    Rinsho Shinkeigaku; 2022 Feb; 62(2):112-122. PubMed ID: 35095045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical characteristics of patients with cerebellar ataxia associated with anti-GAD antibodies.
    Aguiar TS; Fragoso A; Albuquerque CR; Teixeira PF; Souza MV; Zajdenverg L; Alves-Leon SV; Rodacki M; Lima MA
    Arq Neuropsiquiatr; 2017 Mar; 75(3):142-146. PubMed ID: 28355320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glutamic acid decarboxylase autoantibodies and neurological disorders.
    Vianello M; Tavolato B; Giometto B
    Neurol Sci; 2002 Oct; 23(4):145-51. PubMed ID: 12536283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-GAD Antibody, Seizures, Cerebellar Ataxias and Vitiligo: A Diagnostic Challenge.
    Flores-Cantu H; Camara-Lemarroy CR; Calderon-Hernandez HJ; Zapata-Rivera MA; Villareal-Perez JZ; Villareal-Velazquez HJ
    Cerebellum; 2015 Jun; 14(3):375-7. PubMed ID: 25575726
    [No Abstract]   [Full Text] [Related]  

  • 26. Anti-GAD Antibodies and the Cerebellum: Where Do We Stand?
    Manto M; Mitoma H; Hampe CS
    Cerebellum; 2019 Apr; 18(2):153-156. PubMed ID: 30343467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Presynaptic inhibition of cerebellar GABAergic transmission by glutamate decarboxylase autoantibodies in progressive cerebellar ataxia.
    Takenoshita H; Shizuka-Ikeda M; Mitoma H; Song S; Harigaya Y; Igeta Y; Yaguchi M; Ishida K; Shoji M; Tanaka M; Mizusawa H; Okamoto K
    J Neurol Neurosurg Psychiatry; 2001 Mar; 70(3):386-9. PubMed ID: 11181864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of steroid treatment in cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies.
    Virgilio R; Corti S; Agazzi P; Santoro D; Lanfranconi S; Candelise L; Bresolin N; Comi GP; Bersano A
    J Neurol Neurosurg Psychiatry; 2009 Jan; 80(1):95-6. PubMed ID: 19091718
    [No Abstract]   [Full Text] [Related]  

  • 29. [Ataxic form of Hashimoto's encephalopathy].
    Yoneda M
    Rinsho Shinkeigaku; 2012; 52(11):1369-71. PubMed ID: 23196621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Opsoclonus-myoclonus-ataxia syndrome with autoantibodies to glutamic acid decarboxylase.
    Markakis I; Alexiou E; Xifaras M; Gekas G; Rombos A
    Clin Neurol Neurosurg; 2008 Jun; 110(6):619-21. PubMed ID: 18433986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute Cerebellar Ataxia Associated with Anti-glutamic Acid Decarboxylase Antibodies Mimicking Miller Fisher Syndrome.
    Nakamura Y; Nakajima H; Hosokawa T; Yamane K; Ishida S; Kimura F
    Intern Med; 2018 Jan; 57(2):269-271. PubMed ID: 29093402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases.
    Manto MU; Laute MA; Aguera M; Rogemond V; Pandolfo M; Honnorat J
    Ann Neurol; 2007 Jun; 61(6):544-51. PubMed ID: 17600364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical presentation of immune-mediated cerebellar ataxia.
    Demarquay G; Honnorat J
    Rev Neurol (Paris); 2011 May; 167(5):408-17. PubMed ID: 21055784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients.
    Honnorat J; Saiz A; Giometto B; Vincent A; Brieva L; de Andres C; Maestre J; Fabien N; Vighetto A; Casamitjana R; Thivolet C; Tavolato B; Antoine J; Trouillas P; Graus F
    Arch Neurol; 2001 Feb; 58(2):225-30. PubMed ID: 11176960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autoimmunity as a prognostic factor in sporadic adult onset cerebellar ataxia.
    Sivera R; Martín N; Boscá I; Sevilla T; Muelas N; Azorín I; Vílchez JJ; Bolonio M; Donat E; Ribes-Koninckx C; Bataller L
    J Neurol; 2012 May; 259(5):851-4. PubMed ID: 21984193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor.
    Sillevis Smitt P; Kinoshita A; De Leeuw B; Moll W; Coesmans M; Jaarsma D; Henzen-Logmans S; Vecht C; De Zeeuw C; Sekiyama N; Nakanishi S; Shigemoto R
    N Engl J Med; 2000 Jan; 342(1):21-7. PubMed ID: 10620645
    [No Abstract]   [Full Text] [Related]  

  • 37. Spontaneous downbeat nystagmus as a clue for the diagnosis of ataxia associated with anti-GAD antibodies.
    Vale TC; Pedroso JL; Alquéres RA; Dutra LA; Barsottini OG
    J Neurol Sci; 2015 Dec; 359(1-2):21-3. PubMed ID: 26671081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GABA-A receptor impairment in cerebellar ataxia with anti-glutamic acid decarboxylase antibodies.
    Hosoi Y; Suzuki-Sakao M; Terada T; Konishi T; Ouchi Y; Miyajima H; Kono S
    J Neurol; 2013 Dec; 260(12):3086-92. PubMed ID: 24091766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progressive hearing loss and cerebellar ataxia in anti-Ma2-associated autoimmune encephalitis.
    Souza PV; Bortholin T; Pinto WB; Santos AJ
    Arq Neuropsiquiatr; 2017 Jan; 75(1):74-75. PubMed ID: 28099568
    [No Abstract]   [Full Text] [Related]  

  • 40. Intravenous immunoglobulin and rituximab for cerebellar ataxia with glutamic acid decarboxylase autoantibodies.
    Planche V; Marques A; Ulla M; Ruivard M; Durif F
    Cerebellum; 2014 Jun; 13(3):318-22. PubMed ID: 24218114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.